LOGIN
COA 2024: Core Decompression Plus Autologous Bone Marrow Derived MSCs for Femoral Osteonecrosis
June 2024
COA 2024: Core Decompression Plus Autologous Bone Marrow Derived MSCs for Femoral Osteonecrosis
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Autologous Bone Marrow Derived Mesenchymal Stem Cell Therapy Combined With Core Decompression has Better Outcome Than Core Decompression Alone for Early-Stage Osteonecrosis of Femoral Head
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
Thirty-eight patients (50 hips) with early-stage osteonecrosis of the femoral head were randomized to receive autologous bone marrow derived mesenchymal stem cells (BM-MSCs) combined with core decompression (n=18, 26 hips) or core decompression alone (n=20, 24 hips). The outcomes of interest included pain reduction, measured by the Visual Analog Scale (VAS), the Harris Hip Score (HHS), and the mod...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.